Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say
Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.
How this was made
The 30-second read
Why it matters
The $13 million settlement resolves a long‑running anti‑kickback investigation and imposes five years of federal oversight, which may affect future profitability and risk perception.
Market read
The settlement introduces a new regulatory risk for Quest Diagnostics, potentially pressuring its stock modestly.
What to watch
Potential for stricter oversight of lab billing practices could affect future contracts and margins.
Background
Quest Diagnostics is a leading U.S. medical‑testing laboratory that reported $11 billion revenue in 2025.
Ticker impact
Quest Diagnostics settled a federal anti‑kickback case for over $13 million, a new enforcement action disclosed for the first time.
likely modest downside as investors price in the settlement and heightened regulatory scrutiny
Enforcement actions of this size are uncommon for a large‑cap lab services firm and can affect earnings outlook and reputation.
Market effects
May raise compliance concerns for other medical‑testing and health‑care service providers.
Limited to U.S. health‑care sector; no broader market effect.
Low; primarily a U.S. regulatory matter.
Counterpoint
The settlement amount is relatively small versus Quest's $11 billion revenue, so the impact on the stock could be negligible.
Key entities
- companyQuest Diagnostics
U.S. medical‑testing lab (ticker DGX) settling a federal anti‑kickback case.
- government_agencyU.S. Department of Health and Human Services
Oversight agency conducting the five‑year audit of Quest.


